MedTrace Logo

A Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of YPI 011 to Rabeprazole in Healthy Adult Subjects

NCT04703868 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2024-01-24

No results posted yet for this study

Summary

A study to compare the safety, pharmacokinetics and pharmacodynamics of YPI 011 to Rabeprazole in healthy adult subjects

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Rabeprazole Sodium 10mg

Part A: 1 tablet administered before the breakfast during 7 days

DRUG

Rabeprazole Sodium 20mg

Part B: 1 tablet administered before the breakfast during 7 days

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Yungjin Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Seunghwan Lee, M.D., Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-13
Primary Completion
2021-06-01
Completion
2021-06-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04703868 on ClinicalTrials.gov